

ABSTRACT

Peptides which bind to leukocytes are conjugated with drugs. Advantageously, the peptide-drug conjugates interfere with ICAM-1/LFA-1 interactions and are internalized by leukocytes, whereby the drug portion of the conjugate exerts potent toxic side effects against targeted cells with minimal adverse side effects. Preferred conjugates include 4-30 mer peptides derived from ICAM-1 or LFA-1 coupled with drugs effective against leukocyte-related diseases.